Royalty Pharma

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Royalty Pharma reports robust Q4 performance and strategic growth outlook

Royalty Pharma's Q4 2022 earnings call highlighted strong financial performance, efficient cash flow management, and strategic acquisitions. While facing challenges in certain product sales trajectories and market conditions, the company remains focused on innovation and long-term success in the life sciences industry.

Royalty Pharma reports robust Q1 performance and raises capital deployment guidance

Royalty Pharma's Q1 2023 earnings call highlighted strong financial performance, strategic portfolio expansion, and disciplined capital deployment. The company's robust financial health, selective investment approach, and optimistic outlook on market opportunities position them for continued growth. Challenges in deal flow prediction and balancing investments underscore the need for strategic planning and adaptability in a competitive market landscape.

Royalty Pharma (RPRX) reports robust Q2 results amidst regulatory challenges

Royalty Pharma's Q2 performance reflects resilience and growth, supported by strategic initiatives and strong financial metrics. While facing challenges related to regulatory impacts and investor sentiment, the company is focused on leveraging opportunities in attracting investors, educating about its business model, and expanding capital deployment for future growth.

Royalty Pharma reports robust Q3 performance and optimistic growth outlook

Royalty Pharma's Q3 earnings call showcased strong financial performance, active capital allocation, and a focus on shareholder value creation. The company's robust financial model, emphasis on tailored solutions, and optimism about portfolio growth position it well for future opportunities.

Royalty Pharma reports robust 2023 performance and outlines growth strategies

Royalty Pharma's strong performance in 2023 and strategic acquisitions position the company for continued growth in 2024.
Challenges include legal uncertainties and managing shareholder turnover, while opportunities exist in innovative investments and enhanced investor relations.
The company's focus on transparency and attracting long-term investors underscores its commitment to sustainable growth.

Royalty Pharma reports strong Q1 growth and strategic acquisitions

Royalty Pharma's Q1 performance reflects growth and strategic acquisitions, positioning the company for future success.
While facing challenges related to safety concerns and short-term portfolio fluctuations, Royalty Pharma remains focused on growth.
The company's emphasis on identifying high-potential drugs and upcoming milestones underscores a promising outlook for investors.

Royalty Pharma reports robust Q3 growth and eyes innovative therapies

Royalty Pharma's Q3 performance reflects strong growth and strategic decision-making, positioning the company for continued success.
Despite challenges in market penetration and administration, Royalty Pharma remains optimistic about its growth prospects and innovative therapies.
The company's focus on synthetic royalties, strategic acquisitions, and financial discipline underpin its resilience and potential for future expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

An innovative model and a diversified base make Royalty Pharma stock interesting, particularly if a recent pullback continues
The post Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					Why Everyone Is Investing in 5G All WRONG				
			
					
				
					America’s #1 Stock Picker Reveals His Next 1,000% Winner				
			
					
				
					Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company				
			
					
				
					Radical New Battery Could Dismantle Oil Markets

Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO

Inovio Pharmaceuticals

Moderna

Novavax

Sanofi

Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its therapies to treat COVID-19.

Nasdaq's $1.2 trillion biotech index draws Europe's COVID drug hunters

Continental Resources

Twenty-First Century Fox

Groupon

Axis Capital

Cardtronics

Con Ed

Epizyme

Vistra Energy

WesBanco

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Notable Insider Buys: Continental Resources, Fox, Groupon And More

DocuSign

Spotify

Uber

Vroom

Warner Music Group

ZoomInfo Technologies

The market for initial public offerings has come roaring back, coinciding with the recovery of stock markets, hope for a V-shape economic recovery and a strong IPO market in June.
The post IPO Market Returns To Growth Mode As Booming Biotechs Lead The Charge appeared first on Investor's Business Daily.

IPO Market Returns To Growth Mode As Booming Biotechs Lead The Charge

VIRGINIA BEACH, Va., June 25, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (NASDAQ:RPRX). The company raised $2.18 billion...

New Ventures Portfolio Company, Royalty Pharma, Surges On Public Debut

Royalty Pharma is an interesting business and business model in the biopharmaceutical industry.

Royalty Pharma: An Interesting Business

NEW YORK, June  18, 2020  (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced the closing of the initial public offering of 89,333,920 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a price to the public of $28.00 per share. The size of the IPO was increased from the previously announced 70,000,000 Class A ordinary shares.  The company offered 71,652,250 Class A ordinary shares and the selling shareholders offered 17,681,670 Class A ordinary shares. The number of Class A ordinary shares issued at closing included the exercise in full of the underwriters’ option to purchase 11,652,250 additional Class A ordinary shares from the company.  The Class A ordinary shares began trading on the Nasdaq Global Select Market under the ticker symbol “RPRX” on June 16, 2020.

Royalty Pharma Announces Closing of Initial Public Offering

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.

PreMarket Prep Stock Of The Day: Royalty Pharma

"I think the story is so compelling that it's worth putting on a small position even up here," the "Mad Money" host said.

Royalty Pharma came public in a 'golden age of medical research,' Jim Cramer says

The Royal Treatment: Year's Largest IPO Royalty Pharma Soars 58.9% In First Day Of Trading

The initial public offering was for a pharmaceutical company that doesn't want to make or sell any drugs.

Royalty Pharma Pulls the Off Largest IPO of 2020

Royalty Pharma’s initial public offering (IPO) in the United States priced at the peak of the expected range and raised £1.73 billion on Monday. Royalty’s listing now marks the 2nd largest IPO in the pharmaceutical sector in history.

Royalty Pharma’s market value increases by more than 50% as it begins trading on Tuesday

The Royalty Pharma (RPRX) IPO is currently underway and 'InvestorPlace' has everything investors need to know about the offering.
The post Royalty Pharma IPO: 15 Things for Potential RPRX Stock Investors to Know appeared first on InvestorPlace.

Royalty Pharma IPO: 15 Things for Potential RPRX Stock Investors to Know

Royalty Pharma PLC (NASDAQ: RPRX) entered the market with a bang on Tuesday. The shares went out well above the expected price: at $44.25, after pricing at $28 per share.

Royalty Pharma Enters the Market With a Bang

Royalty Pharma set a record for the largest initial public offering this year, one that drew heightened interest from institutional investors and raised $2.2 billion. Shares soared.

Royalty Pharma IPO Sets Record As Largest Public Offering, Stock Soars

Royalty Pharma PLC RPRX, +63.39% started its public life with a big rally Tuesday, as shares of the buyer of pharmaceutical royalties opened well above the initial public offering price.

Royalty Pharma's stock soars in public debut, as Wall Street cheers the year's largest IPO

Royalty Pharma Plc RPRX, +52.03% priced its initial public offering late Monday at $28 a share, the top end of its price range, and upsized the deal, suggesting strong demand from investors.

Royalty Pharma raises $2.2 billion in biggest IPO of the year so far

The IPO of Royalty Pharma, a company that collects royalties from drug sales and also invests in new treatments, is expected to be biggest IPO This year. It begins trading Tuesday.

News for Royalty Pharma Stock (RPRX)